Free Trial
NASDAQ:INM

InMed Pharmaceuticals (INM) Stock Price, News & Analysis

InMed Pharmaceuticals logo
$2.06 -0.58 (-21.97%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$2.20 +0.14 (+6.60%)
As of 03/28/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About InMed Pharmaceuticals Stock (NASDAQ:INM)

Key Stats

Today's Range
$2.06
$2.66
50-Day Range
$2.06
$5.05
52-Week Range
$2.06
$15.70
Volume
37,830 shs
Average Volume
228,725 shs
Market Capitalization
$2.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Remove Ads

InMed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

INM MarketRank™: 

InMed Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for InMed Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InMed Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InMed Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InMed Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about InMed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.05% of the float of InMed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InMed Pharmaceuticals has recently decreased by 19.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    InMed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    InMed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.05% of the float of InMed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in InMed Pharmaceuticals has recently decreased by 19.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    InMed Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for INM on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.85% of the stock of InMed Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 20.12% of the stock of InMed Pharmaceuticals is held by institutions.

  • Read more about InMed Pharmaceuticals' insider trading history.
Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Stock News Headlines

Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

INM Stock Analysis - Frequently Asked Questions

InMed Pharmaceuticals' stock was trading at $4.74 on January 1st, 2025. Since then, INM stock has decreased by 56.5% and is now trading at $2.06.
View the best growth stocks for 2025 here
.

InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its earnings results on Wednesday, February, 12th. The company reported ($3.64) earnings per share (EPS) for the quarter. InMed Pharmaceuticals had a negative net margin of 163.75% and a negative trailing twelve-month return on equity of 90.74%.

InMed Pharmaceuticals's stock reverse split before market open on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

InMed Pharmaceuticals' top institutional shareholders include AdvisorShares Investments LLC (5.34%). Insiders that own company stock include Eric A Adams and Andrew Hull.
View institutional ownership trends
.

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL).

Company Calendar

Last Earnings
2/12/2025
Today
3/30/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INM
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,680,000.00
Net Margins
-163.75%
Pretax Margin
-163.58%

Debt

Sales & Book Value

Annual Sales
$4.83 million
Price / Cash Flow
N/A
Book Value
$5.12 per share
Price / Book
0.40

Miscellaneous

Free Float
711,000
Market Cap
$2.49 million
Optionable
Not Optionable
Beta
0.18
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:INM) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners